IE 11 is not supported. For an optimal experience visit our site on another browser.

BioNeutral Group's Chief Scientist Receives Invitation From the Minister of Health of Goa, India

/ Source: GlobeNewswire

NEWARK, N.J., Oct. 4, 2010 (GLOBE NEWSWIRE) -- BioNeutral Group, Inc. (OTCBB:BONU), a specialty chemical technology-based life science company, has received an invitation from Shri. Vishwajit Pratapsingh Rane, Minister of Health and Agriculture of Goa, India for its Chief Scientist, Dr. Andrew Kielbania, to meet the Minister and representatives of the Ministry of Health. The Minister wants to explore how BioNeutral's new generation of specialty antimicrobial disinfectants, cleaners and toxic gas neutralizers could improve the health and environment of Goa.

Dr. Andy Kielbania, Chief Scientist of BioNeutral Group, Inc. said: "We are honored by this invitation from the Minister of Health. We believe that both our innovative Ygiene™ antimicrobial products and our Ogiene™ cleaners and toxic gas eliminators will be well received by the Ministry. We know that our products can deliver significant beneficial attributes to improve the healthcare of Goa and we should have very productive discussions."

About Goa, India:

Goa is one of India's richest states with the highest GDP per capita in India. It is located in southwest India on the Arabian Sea. With its mild climate, destination resorts and cosmopolitan cities, international tourism is an important industry. Other major industries of Goa include agricultural products, chemicals, pharmaceuticals and hospitality.

For more information, see

About BioNeutral Group, Inc.:

Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene and Ogiene, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene(TM) brand have been submitted to the EPA for approval for sale in the United States and has already been approved for sale in Germany and is permitted to be sold in the UK, France and Sweden. Ogiene(TM) based AutoNeutral(TM) Odor Eliminator is currently commercially available in the United States. For more information, see

Forward-Looking Statements

This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.

CONTACT: Stern & Co. PR/Media Relations: Richard Stern 212-888-0044 Hayden IR Investor Relations: Brett Maas 646/536-7331 BioNeutral Group Inc. Stephen J. Browand, President and CEO 973-286-2899